US equities |
SPCX $160.57 ▲+0.00% MU $1,035.84 ▲+0.00% NVDA $230.48 ▲+0.00% AAPL $340.42 ▲+0.00% SNDK $1,609.46 ▲+0.00% LITE $1,048.60 ▲+0.00% INTC $107.08 ▲+0.00% AMD $620.68 ▲+0.00%
FinancialContent

Gemini Therapeutics, Inc. - Common Stock (NQ:GMTX)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Dec 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gemini Therapeutics, Inc. - Common Stock

News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
News headline image
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Provides Corporate Update
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Provides GEM103 Program Update
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Poster Presentation at AAO 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in Upcoming Investor Conferences
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
From Gemini Therapeutics, Inc.
Via Business Wire